Savara (NASDAQ:SVRA) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

Other research analysts also recently issued reports about the company. Canaccord Genuity dropped their price target on Savara from $22.00 to $15.00 and set a buy rating on the stock in a research note on Thursday, June 13th. JMP Securities downgraded Savara from an outperform rating to a market perform rating and set a $2.60 price target on the stock. in a research note on Thursday, June 13th. Evercore ISI set a $17.00 price target on Savara and gave the stock a buy rating in a research note on Monday, August 12th. LADENBURG THALM/SH SH reaffirmed a hold rating and set a $1.00 price target on shares of Savara in a research note on Thursday, October 3rd. Finally, BidaskClub downgraded Savara from a strong-buy rating to a buy rating in a research note on Friday, June 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Savara currently has a consensus rating of Hold and a consensus target price of $9.09.



Shares of NASDAQ:SVRA traded up $0.01 during midday trading on Thursday, reaching $0.88. The company’s stock had a trading volume of 5,157 shares, compared to its average volume of 676,170. The firm has a market capitalization of $37.74 million, a price-to-earnings ratio of -0.70 and a beta of 0.20. The company has a debt-to-equity ratio of 0.22, a quick ratio of 12.61 and a current ratio of 12.61. The firm has a 50 day moving average price of $2.21 and a two-hundred day moving average price of $5.50. Savara has a fifty-two week low of $0.82 and a fifty-two week high of $11.96.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. As a group, research analysts anticipate that Savara will post -1.7 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its stake in Savara by 43.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,475,000 shares of the company’s stock worth $8,236,000 after buying an additional 1,050,000 shares during the period. BlackRock Inc. raised its stake in Savara by 11.0% during the 2nd quarter. BlackRock Inc. now owns 2,438,608 shares of the company’s stock worth $5,779,000 after buying an additional 241,117 shares during the period. Vanguard Group Inc. raised its stake in Savara by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,250,254 shares of the company’s stock worth $2,963,000 after buying an additional 10,794 shares during the period. Northern Trust Corp raised its stake in Savara by 1.5% during the 2nd quarter. Northern Trust Corp now owns 344,176 shares of the company’s stock worth $815,000 after buying an additional 5,072 shares during the period. Finally, Eversept Partners LP purchased a new stake in shares of Savara in the second quarter worth approximately $574,000. 41.19% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Article: What is a death cross?

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.